Literature DB >> 21724423

Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient.

Poh-Shiow Yeh1, Hsiu-Nien Shen, Tai-Yuan Chen.   

Abstract

Nonconvulsive status epilepticus (NCSE) is a heterogeneous disorder with different seizure types and diverse etiologies, and is mainly characterized by altered consciousness. The recognition of NCSE is more challenging than generalized convulsive SE, and diagnosis and treatment are often delayed. Therefore, some cases can evolve into refractory SE and become pharmacoresistant even with GABAergic anesthetics. Herein we report the successful clinical experience of pharmacoresistant complex partial SE treated with ketamine. An elderly woman was profoundly stuporous and had relentless clonic movements of the right hand and forearm. Electroencephalography revealed repetitive periodic lateralized epileptiform discharges (PLEDs). There was a poor clinical response to standard anticonvulsants and GABAergic anesthetics. Both the clinical and electroencephalographic SE were controlled after intravenous ketamine therapy. Rebound refractory NCSE occurred about six days after discontinuing the intravenous ketamine, which was successfully terminated by oral ketamine treatment. There were no adverse effects observed.
Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724423     DOI: 10.1016/j.seizure.2011.06.001

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  8 in total

1.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

2.  Early ketamine to treat refractory status epilepticus.

Authors:  Andreas H Kramer
Journal:  Neurocrit Care       Date:  2012-04       Impact factor: 3.210

3.  Ketamine for medically refractory status epilepticus after elective aneurysm clipping.

Authors:  F A Zeiler; A M Kaufmann; L M Gillman; M West; J Silvaggio
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

Review 4.  NMDA antagonists for refractory seizures.

Authors:  F A Zeiler; J Teitelbaum; L M Gillman; M West
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

Review 5.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

6.  Transition from intravenous to enteral ketamine for treatment of nonconvulsive status epilepticus.

Authors:  Michael A Pizzi; Prasuna Kamireddi; William O Tatum; Jerry J Shih; Daniel A Jackson; William D Freeman
Journal:  J Intensive Care       Date:  2017-08-08

7.  (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study.

Authors:  Julia Höfler; Alexandra Rohracher; Gudrun Kalss; Georg Zimmermann; Judith Dobesberger; Georg Pilz; Markus Leitinger; Giorgi Kuchukhidze; Kevin Butz; Alexandra Taylor; Helmut Novak; Eugen Trinka
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 8.  CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy.

Authors:  Immaculate M Langmia; Katja S Just; Sabrina Yamoune; Jürgen Brockmöller; Collen Masimirembwa; Julia C Stingl
Journal:  Front Genet       Date:  2021-07-12       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.